Amaral MD - Search Results

1

Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9.

Pinto MC, Quaresma MC, Silva IAL, Railean V, Ramalho SS, Amaral MD. Pinto MC, et al. Among authors: amaral md. Int J Mol Sci. 2021 Dec 2;22(23):13064. doi: 10.3390/ijms222313064. Int J Mol Sci. 2021. PMID: 34884866 Free PMC article.

2

A comparison of 14 antibodies for the biochemical detection of the cystic fibrosis transmembrane conductance regulator protein.

Farinha CM, Mendes F, Roxo-Rosa M, Penque D, Amaral MD. Farinha CM, et al. Among authors: amaral md. Mol Cell Probes. 2004 Aug;18(4):235-42. doi: 10.1016/j.mcp.2004.03.005. Mol Cell Probes. 2004. PMID: 15271383

3

Proteomics techniques for cystic fibrosis research.

Roxo-Rosa M, Davezac N, Bensalem N, Majumder M, Heda GD, Simas A, Penque D, Amaral MD, Lukacs GL, Edelman A. Roxo-Rosa M, et al. Among authors: amaral md. J Cyst Fibros. 2004 Aug;3 Suppl 2:85-9. doi: 10.1016/j.jcf.2004.05.019. J Cyst Fibros. 2004. PMID: 15463934 Free article. Review.

4

Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin.

Farinha CM, Amaral MD. Farinha CM, et al. Among authors: amaral md. Mol Cell Biol. 2005 Jun;25(12):5242-52. doi: 10.1128/MCB.25.12.5242-5252.2005. Mol Cell Biol. 2005. PMID: 15923638 Free PMC article.

5

Characterization of novel airway submucosal gland cell models for cystic fibrosis studies.

da Paula AC, Ramalho AS, Farinha CM, Cheung J, Maurisse R, Gruenert DC, Ousingsawat J, Kunzelmann K, Amaral MD. da Paula AC, et al. Among authors: amaral md. Cell Physiol Biochem. 2005;15(6):251-62. doi: 10.1159/000087235. Cell Physiol Biochem. 2005. PMID: 16037690 Free article.

6

Revertant mutants G550E and 4RK rescue cystic fibrosis mutants in the first nucleotide-binding domain of CFTR by different mechanisms.

Roxo-Rosa M, Xu Z, Schmidt A, Neto M, Cai Z, Soares CM, Sheppard DN, Amaral MD. Roxo-Rosa M, et al. Among authors: amaral md. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17891-6. doi: 10.1073/pnas.0608312103. Epub 2006 Nov 10. Proc Natl Acad Sci U S A. 2006. PMID: 17098864 Free PMC article.

7

Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.

Amaral MD, Kunzelmann K. Amaral MD, et al. Trends Pharmacol Sci. 2007 Jul;28(7):334-41. doi: 10.1016/j.tips.2007.05.004. Epub 2007 Jun 18. Trends Pharmacol Sci. 2007. PMID: 17573123 Review.

8

Solubilizing mutations used to crystallize one CFTR domain attenuate the trafficking and channel defects caused by the major cystic fibrosis mutation.

Pissarra LS, Farinha CM, Xu Z, Schmidt A, Thibodeau PH, Cai Z, Thomas PJ, Sheppard DN, Amaral MD. Pissarra LS, et al. Among authors: amaral md. Chem Biol. 2008 Jan;15(1):62-9. doi: 10.1016/j.chembiol.2007.11.012. Chem Biol. 2008. PMID: 18215773

9

Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator.

Schmidt A, Hughes LK, Cai Z, Mendes F, Li H, Sheppard DN, Amaral MD. Schmidt A, et al. Among authors: amaral md. Br J Pharmacol. 2008 Mar;153(6):1311-23. doi: 10.1038/sj.bjp.0707663. Epub 2008 Jan 28. Br J Pharmacol. 2008. PMID: 18223673 Free PMC article.

10

Targeting CFTR: how to treat cystic fibrosis by CFTR-repairing therapies.

Amaral MD. Amaral MD. Curr Drug Targets. 2011 May;12(5):683-93. doi: 10.2174/138945011795378586. Curr Drug Targets. 2011. PMID: 21039334 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

209 results

Search Page